Award Number: W81XWH-12-1-0578

TITLE: Targeting Autophagy for the Treatment of TSC and LAM

PRINCIPAL INVESTIGATOR: Elizabeth Henske

CONTRACTING ORGANIZATION:
Brigham and Women’s Hospital
Boston, MA 02115-0110

REPORT DATE: October 2013

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

    X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Targeting Autophagy for the Treatment of TSC and LAM

1. REPORT DATE (DD-MM-YYYY)  
October 2013

2. REPORT TYPE  
Annual

3. DATES COVERED (From - To)  
30 September 2012 - 29 September 2013

4. TITLE AND SUBTITLE  
Targeting Autophagy for the Treatment of TSC and LAM

5a. CONTRACT NUMBER  
W81XWH-12-1-0578

5b. GRANT NUMBER  
W81XWH-12-1-0578

5c. PROGRAM ELEMENT NUMBER

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

6. AUTHOR(S)  
Elizabeth Henske

E-Mail: EHENSKE@PARTNERS.ORG

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  
Brigham and Women’s Hospital  
One Blackfan Circle, Karp Bldg, 6th Fl,  
Boston, MA 02115-5713

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR’s ACRONYM(S)  
USAMRMC

11. SPONSOR/MONITOR’s REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT  
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT : Lymphangioleiomyomatosis (LAM), a disease that primarily affects women, is characterized by cystic lung destruction. LAM results from the proliferation of LAM cells that harbor mutations in the TSC1 or TSC2 genes, leading to activation of the mammalian target of rapamycin complex 1 (mTORC1). Recently, sirolimus (rapamycin) has been shown to stabilize lung function decline and decrease angiomyolipoma tumor size. Discontinuation of therapy results in progression of lung function decline and tumor growth, suggesting that continuous use is required to maintain its beneficial effects. Autophagy (self eating) is a mechanism by which tumor cells recycle proteins and organelles. Blocking TORC1, a known autophagy inhibitor, with rapamycin increases autophagy and promotes survival of TSC2-deficient cells. The Sirolimus and Autophagy Inhibition in LAM (SAIL) trial is a phase I clinical trial to test the safety and tolerability of a combination of hydroxychloroquine and sirolimus in women with LAM.

We will measure the effect of therapy using the following secondary endpoints:
  1. Forced expiratory volume in 1 sec (FEV1), 2. Forced vital capacity (FVC), 3. 6-minute walk test (6MWT), 4. Angiomyolipoma size, 5. Quality of life and 6. VEGF-D serum levels

15. SUBJECT TERMS  
sirolimus, hydroxychloroquine, lymphangiomyoleiomatosis

16. SECURITY CLASSIFICATION OF:  
U

17. LIMITATION OF ABSTRACT

18. NUMBER OF PAGES  
5

19a. NAME OF RESPONSIBLE PERSON  
USAMRMC

19b. TELEPHONE NUMBER (Include area code)  

UU 5

UU

UU 5

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18
# Table of Contents

<table>
<thead>
<tr>
<th>Introduction</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>BODY</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>4-5</td>
</tr>
<tr>
<td>Conclusion</td>
<td>5</td>
</tr>
<tr>
<td>References</td>
<td>5</td>
</tr>
<tr>
<td>Appendices</td>
<td>5</td>
</tr>
</tbody>
</table>
INTRODUCTION:
This is a phase I, open label, dose escalating, two-center trial of the combination of sirolimus and hydroxychloroquine in women with LAM. The combination of sirolimus (2mg adjusted to keep trough levels between 5-15ng/ml) and hydroxychloroquine (200mg or 400mg) will be taken orally daily for 6 months. Up to 18 female subjects ages 18 and older with LAM will be enrolled at Brigham and Women's Hospital in Boston, MA and the National Heart, Lung, and Blood Institute in Bethesda, MD. The primary endpoint of this study is safety and tolerability of the combination of sirolimus and hydroxychloroquine in LAM patients. This trial will also investigate whether, in LAM patients, 6 month of combination therapy results in improvement of indicators of disease, and whether the gains are sustained after stopping therapy. The role of LAM-specific peripheral blood signature to predict rates of disease progression and determine responsiveness to combination therapy will also be investigated. The projected duration of the trial is 4 years.

KEY WORDS:
sirolimus, hydroxychloroquine, lymphangiomyoleiomatosis

OVERALL PROJECT SUMMARY:
This study is planning to enroll up to a total of 18 subjects at Brigham and Women’s Hospital (BWH) and the National Heart, Lung, and Blood Institute (NHLBI). BWH obtained IRB approval on 6/21/2013 and is activated and enrolling subjects. The NHLBI received IRB approval on 9/20/2013 and has completed the site initiation visit. Four subjects were screened at BWH. Three women have been enrolled. One subject is still in screening. All three subjects have completed at least an 8 week course of hydroxychloroquine and sirolimus. Two subjects have completed a 24 week course of study drug. No serious adverse events have been reported.

There have been 4 amendments to the protocol.
Summary of Amendment 01
- The Department of Defense was added to the consent form. A prescreening script and prescreening questionnaire was added to the protocol to help identify eligible subjects for screening.

Summary of Amendment 02
- A study drug information sheet was created to distribute to enrolled subjects as requested by the DSMB during the meeting on 11/5/2012.
- The DSMB Charter was amended to include an additional DSMB meeting to review analysis data if data is collected before the 6 month timepoint.

Summary of Amendment 03
- Instructions for use of contraceptives were clarified in the protocol and consent form.
- Summary of Amendment 04
- A spirometry measurement was added to visit 6
- Urinalysis was included in visit 6
- Urine pregnancy was moved from visit 7 to visit 6
- Dose limiting toxicity for visual disturbances was further defined to include “Any visual disturbance as outlined in the risk section of this protocol or in the hydroxychloroquine package insert.”
- Risk of stopping study drugs was added to the risk section of the protocol
Two DSMB meetings have been held on 11/5/2012 and 6/13/2013. Per protocol, the DSMB convened for an interim analysis of safety data on 8/6/2013. Safety data was reviewed and the DSMB approved the dose escalation. A second interim analysis will occur once 3 more patients have completed an 8 week course of therapy with sirolimus and hydroxychloroquine at 400mg/day.

The plan from the originally approved SOW will remain the same in the upcoming year.

<table>
<thead>
<tr>
<th>Subject Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject ID</td>
</tr>
<tr>
<td>01-001</td>
</tr>
<tr>
<td>01-002</td>
</tr>
<tr>
<td>01-003</td>
</tr>
<tr>
<td>01-004</td>
</tr>
</tbody>
</table>

**KEY RESEARCH ACCOMPLISHMENTS**: Nothing to report

**CONCLUSION**: Nothing to report

**PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS**: Nothing to report

**INVENTIONS, PATENTS, AND LICENSES**: Nothing to report

**REPORTABLE OUTCOMES**: Nothing to report

**OTHER ACHIEVEMENTS**: Nothing to report